Is palliative laparoscopic hyperthermic intraperitoneal chemotherapy effective in patients with malignant hemorrhagic ascites?
Fiche publication
Date publication
janvier 2012
Journal
Case reports in gastroenterology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BOUCHE Olivier
Tous les auteurs :
de Mestier L, Volet J, Scaglia E, Msika S, Kianmanesh R, Bouché O
Lien Pubmed
Résumé
Malignant hemorrhagic ascites may complicate the terminal evolution of digestive cancers with peritoneal carcinomatosis. It has a bad influence on prognosis and may severely impair patients' quality of life. Palliative laparoscopic hyperthermic intraperitoneal chemotherapy (HIPEC) has been proposed to treat debilitating malignant ascites. Two cases of peritoneal carcinomatosis causing hemorrhagic ascites and severe anemia that needed iterative blood transfusions are reported. These patients were treated by laparoscopic HIPEC (mitomycin C and cisplatin with an inflow temperature of 43°C), resulting in cessation of peritoneal bleeding. No postoperative complication or relapse of ascites occurred during the following months. No more blood transfusion was needed. Laparoscopic HIPEC might be an effective and safe therapeutic option to consider in patients with malignant hemorrhagic ascites.
Mots clés
Ascites, Cancer, Hemoperitoneum, Hyperthermic intraperitoneal chemotherapy, Intraperitoneal drug delivery, Laparoscopy, Palliative surgery
Référence
Case Rep Gastroenterol. 2012 Jan;6(1):166-70